

HR 8641

Orphan Drug COVID-19 Mitigation Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Aug 2, 2022

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Aug 2, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/8641>

Sponsor

Name: Rep. Gottheimer, Josh [D-NJ-5]

Party: Democratic • **State:** NJ • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bacon, Don [R-NE-2]	R · NE		Aug 2, 2022
Rep. Dean, Madeleine [D-PA-4]	D · PA		Aug 2, 2022
Rep. Schrader, Kurt [D-OR-5]	D · OR		Oct 21, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Aug 2, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Aug 2, 2022)

Orphan Drug COVID-19 Mitigation Act of 2022

This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.

Actions Timeline

- **Aug 2, 2022:** Introduced in House
- **Aug 2, 2022:** Referred to the House Committee on Energy and Commerce.